Monitor for IOP elevation immediately following intravitreal inj. Risk of intravitreal inj-related reactions eg, endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear, & iatrogenic traumatic cataract; transient IOP increases. Caution in patients w/ poorly controlled glaucoma; risk factors for retinal pigment epithelial tears. W/hold treatment in patients w/ rhegmatogenous retinal detachment, stage 3 or 4 macular holes, retinal break; treatment-related decrease in best corrected visual acuity of ≥30 letters compared w/ last assessment; IOP ≥30 mmHg; subretinal haemorrhage involving centre of fovea or if haemorrhage size is ≥50% of total lesion area; performed or planned intraocular surgery w/in previous or next 28 days. Safety & efficacy of bilateral treatment have not been studied. Reports of systemic adverse events including arterial thromboembolic events. Potential for immunogenicity. Concomitant use w/ other anti-VEGF. Limited experience in nAMD & RVO patients ≥85 yr, & DME patients w/ type I diabetes, patients w/ HbA1c >10%, patients w/ high-risk proliferative diabetic retinopathy, high BP (≥140/90 mmHg) & vascular disease, sustained dosing intervals shorter than every 8 wk, or nAMD, DME, & RVO patients w/ active systemic infections. No experience in diabetic or RVO patients w/ uncontrolled HTN & patients w/ RVO who have failed previous therapy. Should not be taken by patients w/ hypersensitivity to polysorbate. Minor influence on ability to drive & use machines. Women of childbearing potential should use effective contraception during treatment & for at least 3 mth following the last intravitreal inj. Do not use during pregnancy unless potential benefit outweighs potential risk to foetus. Do not use during breast-feeding. No relevant use in the paed population.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
